BRCA2 and cancer: Additionally, certain mutations, such as BRCA1, BRCA2, PALB2, CHEK2, and ATM, are more enriched in mCRPC than in primary localized prostate cancer samples, reflecting the unique biology of cancer progression and castration resistance (Robinson et al. 2015; Henríquez et al. 2021).